Swedish Orphan Biovitrum
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS6
PHASE 3 / 2-35
RECRUITING2
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Anakinra NCT05814159 |
P3 | Active, not recruiting | Still's Disease, Juvenile Onset; Still's Disease, Adult-Onset | 15 | 2025-12-10 (+24 mo) |
| PACIFICA NCT03165734 |
P3 | Active, not recruiting | Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis | 407 | 2026-10-05 (+94 mo) |
| Pacritinib NCT06782373 |
P2 | Recruiting | VEXAS; VEXAS Syndrome | 156 | 2026-12-30 (-7 mo) |
| LIBERTY NCT06716814 |
P3 | Active, not recruiting | Haemophilia A (Moderate or Severe) | 89 | 2027-03 (+7 mo) |
| Avatrombopag 20 mg Oral Tablet NCT07786922 |
P2/3 | Not yet recruiting | Aplastic Anemia | 26 | 2028-06-30 |
| PRESERVE NCT07898774 |
P3 | Recruiting | C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN); Recurrent Glomerular Disease After Kidney Transplantation | 30 | 2031-01-17 |